When clinically indicated, chemo use high for breast cancer

Share this article:
When Clinically Indicated, Chemo Use High for Breast Cancer
When Clinically Indicated, Chemo Use High for Breast Cancer

(HealthDay News) -- Fewer than half of women with localized breast cancer for whom adjuvant chemotherapy is discretionary, either due to clinical factors or age, tend to utilize adjuvant chemotherapy; however, when clinically indicated, women initiate chemotherapy at a high rate, according to research published online Sept. 24 in the Journal of Clinical Oncology.

In a prospective cohort study involving 1,145 women with nonmetastatic breast cancer, Alfred I. Neugut, M.D., Ph.D., of the Columbia University Medical Center in New York City, and colleagues examined the medical and nonmedical factors that influence patient and physician decisions regarding adjuvant chemotherapy.

Chemotherapy was indicated for 34.2 percent of patients; clinically discretionary for 40.1 percent; discretionary based on patient age for 14.8 percent; and was not indicated for 10.9 percent of patients. The researchers found that 90 percent of patients for whom chemotherapy was indicated received it, compared with only 36 percent of those for whom it was discretionary due to clinical factors, and 19 percent for those for whom it was discretionary due to patient age. Patients who did not receive chemotherapy tended to be older with more negative beliefs about treatment efficacy, less positive beliefs relating to chemotherapy, and greater concern regarding adverse events. Clinical predictors of worse outcome correlated with increased chemotherapy initiation among patients for whom chemotherapy was discretionary.

"Women for whom adjuvant chemotherapy is definitively recommended generally initiate chemotherapy at a high rate. Among patients for whom it was discretionary, less than half received chemotherapy," the authors write. "As would be expected, younger age and worse prognostic features are associated with increased rates of chemotherapy initiation in these discretionary groups."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.